Publications by authors named "L Chantrill"
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG).
Clin Colorectal Cancer
December 2024
Background: Panitumumab (pan) plus chemotherapy is a preferred first-line therapy for unresectable RAS and BRAF wild type metastatic colorectal cancer (mCRC). Older patients may not be suitable for combination regimens. We investigated 2 lower intensity pan-containing regimens.
View Article and Find Full Text PDFChemotherapy and radiotherapy for advanced pancreatic cancer.
Cochrane Database Syst Rev
December 2024
Article Synopsis
- Pancreatic cancer is a highly lethal disease with limited treatment options, leading to an updated review of randomized data focused on first-line treatments for advanced cases.
- The review examines the impact of chemotherapy, radiotherapy, or a combination of both on overall survival, severe adverse events, and quality of life for patients with unresectable or metastatic pancreatic cancer.
- A total of 75 studies were analyzed, with 51 included in the meta-analysis, examining various treatment comparisons and finding that the studies generally had low risks for biases in methodology.
Background: Fluoropyrimidine (FP) chemotherapies are commonly prescribed for upper and lower gastrointestinal, breast and head and neck malignancies. Over 16,000 people with cancer require FP chemotherapies per annum in Australia. Between 10 and 40% patients experience grade 3-4 (≥ G3) toxicities that require hospital-based management ± intensive care admission.
View Article and Find Full Text PDFArticle Synopsis
- - The treatment for early-stage non-small cell lung cancer (NSCLC) has evolved from standard adjuvant chemotherapy to incorporating neoadjuvant immunotherapy based on its potential to improve outcomes during surgery.
- - Numerous studies have examined various combinations of chemotherapy and immunotherapy, revealing that some combinations significantly improve pathological response and survival rates.
- - The growing complexity of NSCLC treatment, with over 20 combinations being tested and new agents in development, is reshaping clinical practice and necessitating further research into optimal strategies.
The burden of colorectal cancer (CRC) is high in the Asia-Pacific region, and several countries in this region have among the highest and/or fastest growing rates of CRC in the world. A significant proportion of patients will present with or develop metastatic CRC (mCRC), and BRAF-mutant mCRC represents a particularly aggressive phenotype that is less responsive to standard chemotherapies. In light of recent therapeutic advances, an Asia-Pacific expert consensus panel was convened to develop evidence-based recommendations for the diagnosis, treatment, and management of patients with BRAF-mutant mCRC.
View Article and Find Full Text PDF